4.7 Article

ARID1A loss activates MAPK signaling via DUSP4 downregulation

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance

Zahra Zandi et al.

Summary: This review discusses the role of dual-specificity phosphatases (DUSPs) in therapy resistance and their potential as druggable targets in cancer treatment. Mechanistic insights into the roles of well-known DUSPs in resistance to various cancer therapeutic approaches are provided, as well as the development of DUSP modulators and the preclinical investigations of small molecule inhibitors of DUSP1 and 6.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Review Medicine, General & Internal

Endometrial cancer

Emma J. Crosbie et al.

Summary: Endometrial cancer is the most common gynaecological cancer in high income countries, with a global rise in incidence. Obesity is the major underlying cause, posing challenges for diagnosis and treatment. Early presentation with postmenopausal bleeding ensures cure, but advanced cases have poor prognosis. Minimally invasive surgical staging and targeted chemotherapeutic strategies are important advances.

LANCET (2022)

Article Biochemistry & Molecular Biology

DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway

Mashael S. Al-Mutairi et al.

Summary: MKP-2 plays an important role in Dox-induced EMT and its regulation of the JNK pathway contributes to chemoresistance in breast cancer cells.

MOLECULES (2022)

Review Cell Biology

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

Jayaprakash Mandal et al.

Summary: Chromatin remodeling is a crucial cellular process that plays a key role in cell function. ARID1A is the most commonly mutated chromatin remodeling gene and is closely associated with cancer development. Deficiency in ARID1A leads to tumor progression and dissemination. PARP inhibitors can be used as a therapeutic approach for ARID1A-mutated tumors.

JOURNAL OF BIOMEDICAL SCIENCE (2022)

Article Gastroenterology & Hepatology

Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

Feng-Kun Zhang et al.

Summary: The loss of ARID1A in hepatocellular carcinoma (HCC) cells provides protection against cell death induced by glucose deprivation. ARID1A regulates the USP9X-AMPK axis, and synthetic lethal therapy targeting USP9X may benefit HCC patients with ARID1A mutation.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Biochemistry & Molecular Biology

PKCδ mediates mitochondrial ROS generation and oxidation of HSP60 to relieve RKIP inhibition on MAPK pathway for HCC progression

Jaya Prakash Mandal et al.

Summary: This study revealed that PKC delta interacts with mtROS to trigger HSP60 oxidation for the release of RKIP, activating MAPK and regulating cell migration and G1 cell cycle arrest in HCC. Targeted therapy against key players like PKC delta, RKIP, and HSP60 shows promise in preventing HCC progression.

FREE RADICAL BIOLOGY AND MEDICINE (2021)

Article Oncology

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990?2019

Baoxia Gu et al.

Summary: The incidence of endometrial cancer (EC) has increased globally, while the mortality has decreased worldwide. There are significant differences between countries, and more efforts are needed to alleviate the disease burden of EC.

GYNECOLOGIC ONCOLOGY (2021)

Article Genetics & Heredity

Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers

Takahiro Ito et al.

Summary: Research using a CRISPR paralog targeting library identified that dual inactivation of DUSP4 and DUSP6 selectively impairs growth in NRAS and BRAF mutant cells. Cells resistant to MAPK pathway therapeutics become cross-sensitized to DUSP4 and DUSP6 perturbations, reinforcing the mechanisms of resistance to the inhibitors.

NATURE GENETICS (2021)

Article Medicine, General & Internal

Loss of DUSP4 Expression as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma

Seongsik Bang et al.

Summary: Loss of DUSP4 expression in clear cell renal cell carcinoma is significantly correlated with old age, high histologic grade, tumor necrosis, and high pT category, leading to poor clinical outcomes. Low DUSP4 mRNA expression is also associated with shorter overall survival in patients.

DIAGNOSTICS (2021)

Article Medicine, Research & Experimental

A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening

Youngran Park et al.

Summary: The study introduces a new human endometrial epithelial cell line, hEM3, which is non-transformed, capable of stable in vitro growth, and can serve as a model for studying the pathogenesis of endometrium-related diseases.

LABORATORY INVESTIGATION (2021)

Article Medicine, Research & Experimental

Low DUSP4 Expression Is Associated With Aggressive Phenotypes and Poor Prognosis in Gastric Cancer

Seongsik Bang et al.

Summary: The study revealed that low expression of DUSP4 is associated with aggressive phenotypes of gastric cancer and a poor prognosis, indicating the important role of DUSP4 in the development of gastric cancer.

IN VIVO (2021)

Review Obstetrics & Gynecology

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Ting-Tai Yen et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)

Review Medicine, Research & Experimental

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers

Li Wang et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

Article Oncology

Identification of the Mutational Landscape of Gynecological Malignancies

Suresh Chava et al.

JOURNAL OF CANCER (2020)

Article Oncology

Racial disparities in molecular subtypes of endometrial cancer

Elizabeth A. Dubil et al.

GYNECOLOGIC ONCOLOGY (2018)

Article Cell Biology

Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway

Rui Zhang et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)

Review Oncology

ARID1A gene mutation in ovarian and endometrial cancers

Takashi Takeda et al.

ONCOLOGY REPORTS (2016)

Article Biochemistry & Molecular Biology

Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells

Yohan Suryo Rahmanto et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Article Biochemistry & Molecular Biology

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Benjamin G. Bitler et al.

NATURE MEDICINE (2015)

Article Oncology

Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis

Bin Guan et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

Article Multidisciplinary Sciences

Discovery and saturation analysis of cancer genes across 21 tumour types

Michael S. Lawrence et al.

NATURE (2014)

Article Pathology

Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma

Tsui-Lien Mao et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)

Review Biochemistry & Molecular Biology

ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas

Eleftherios P. Samartzis et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

Review Oncology

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

Jennifer N. Wu et al.

CANCER DISCOVERY (2013)

Editorial Material Obstetrics & Gynecology

Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis

[Anonymous]

WOMENS HEALTH (2010)

Article Medicine, General & Internal

ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas

Kimberly C. Wiegand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Review Biochemistry & Molecular Biology

Dual-specificity phosphatases: critical regulators with diverse cellular targets

Kate I. Patterson et al.

BIOCHEMICAL JOURNAL (2009)

Article Biochemistry & Molecular Biology

Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma

Bozena Dobrzycka et al.

FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2009)

Review Biotechnology & Applied Microbiology

Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses

Kate L. Jeffrey et al.

NATURE REVIEWS DRUG DISCOVERY (2007)

Review Biochemistry & Molecular Biology

Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling

Gang G. Wang et al.

TRENDS IN MOLECULAR MEDICINE (2007)

Article Cell Biology

Diverse physiological functions for dual-specificity MAP kinase phosphatases

Robin J. Dickinson et al.

JOURNAL OF CELL SCIENCE (2006)